Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Receivables (2017 - 2024)

Historic Change in Receivables for Protagonist Therapeutics (PTGX) over the last 8 years, with Q4 2024 value amounting to $165.0 million.

  • Protagonist Therapeutics' Change in Receivables rose 155000.0% to $165.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $155.0 million, marking a year-over-year increase of 145155.16%. This contributed to the annual value of $155.0 million for FY2024, which is 145155.16% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Change in Receivables of $165.0 million as of Q4 2024, which was up 155000.0% from -$43000.0 recorded in Q3 2024.
  • In the past 5 years, Protagonist Therapeutics' Change in Receivables registered a high of $290.0 million during Q1 2024, and its lowest value of -$300.0 million during Q2 2024.
  • Moreover, its 5-year median value for Change in Receivables was -$41000.0 (2023), whereas its average is $7.9 million.
  • Data for Protagonist Therapeutics' Change in Receivables shows a peak YoY increase of 70732195.12% (in 2024) and a maximum YoY decrease of 249990000.0% (in 2024) over the last 5 years.
  • Protagonist Therapeutics' Change in Receivables (Quarter) stood at -$363000.0 in 2020, then tumbled by 195.32% to -$1.1 million in 2021, then skyrocketed by 89.27% to -$115000.0 in 2022, then soared by 8795.65% to $10.0 million in 2023, then soared by 1550.0% to $165.0 million in 2024.
  • Its Change in Receivables stands at $165.0 million for Q4 2024, versus -$43000.0 for Q3 2024 and -$300.0 million for Q2 2024.